Amytracker are small fluorescent molecules for detection of protein aggregates.
Five Amytracker variants are available. All Amytracker variants are designed to bind to the Congo red binding pocket on the amyloid fibril. A minimum of eight in-register parallel-β-strands are required for binding. The Amytracker variants differ in affinity and spectral properties. As Amytracker are structural markers, you can achieve reliable fluorescent labeling of amyloids derived from a variety of amyloidogenic proteins or peptides from different species.
Amytracker are suitable for detecting amyloids in fresh or fixed tissue sections and cells. It is possible to use them for fibrillation assays and for systemic injection in vivo. They are exceptionally photo- and thermostable and allow for easy handling in any application. Amytracker work in a wide range of salt and pH conditions. When the pH is altered during the experiment, pH controls should be included. Amytracker can be used with fluorescence plate readers, fluorescence microscopes and confocal laser scanning microscopes, fluorescence life time imaging, fluorescence cytometry, Total internal reflection fluorescence (TIRF) microscopy and Multiphoton microscopy.
Store your Amytracker product in the fridge and use the opened container within 12 months. Amytracker is for research use only and is not for resale.
Amytracker Mix&Try is our recommended option for starting out with using Amytracker. It contains 10 µL of each variant. Testing the variants will allow you to determine which Amytracker is best suited for your experiments and available instruments.
All Amytracker variants label Aβ plaques and neurofibrillary tangles in tissue sections with AD pathology and α-synuclein aggregates in tissue sections with PD pathology. The optotracers are exceptionally photostable and fluorogenic. The variants differ with regards to affinity, cellular uptake and excitation and emission wavelengths (see Table below). When bound to a target, Amytracker can be imaged using epifluorescence, confocal and superresolution microscopy. Spectral information can be acquired using a fluorescence spectrophotometer. Contact us to learn more about Amytracker applications.
Table: Excitation- and emission wavelengths as well as recommended filter sets.
Amytracker 680 is our red optotracer for labeling protein aggregates with repetitive arrangement of β-sheets. It labels Aβ plaques and neurofibrillary tangles in tissue sections with AD pathology and α-synuclein aggregates in tissue sections with PD pathology. Specifically, Amytracker 680 has been used to study amyloid formation during abnormal coagulation, Lewy body formation in a seeding based neuronal model, accumulation of misfolded proteins in the nucleolus and intracerebral formation of Aβ plaques using multiphoton microscopy. Contact us to learn more about Amytracker applications.
As all our optotracers, Amytracker 680 is exceptionally photostable and fluorogenic. When bound to a target, Amytracker 680 can be imaged using epifluorescence, confocal and superresolution microscopy. Spectral information can be acquired using a fluorescence spectrophotometer. Use recommended filter sets as well as excitation- and emission wavelengths according to the following table.
Table: Excitation- and emission wavelengths as well as recommended filter sets.
Exmax
Emmax
Recommended filter-sets
Amytracker 680
530 nm
680 nm
PI, mCherry, Cy3.5
Amytracker 680 is available in four different formulations (See volumes and prices in the drop-down list below):
Aqueous: 1 mg/ml solution in ultrapure water. The product should be diluted 1:1000 before use. For use in live-cells, sometimes 1:500 is necessary due to uptake limitations. To prevent evaporation of the aqueous solvent, close the container carefully after use, spin down liquid and use up small volumes quickly.
DMSO: 1 mg/ml solution in DMSO to prevent solvent evaporation. The product should be diluted 1:1000 before use. For use in live-cells, sometimes 1:500 is necessary due to uptake limitations.
Solid: 1 mg solid lyophilised in a sterile injection bottle. We recommend dilution to 4 mg/ml in physiological saline followed by intravenous injection with a total dose of 5 mg/KG.
Drop&Shine: 5 ml ready-to-use product in mounting medium. Ideal for use in tissue sections. Add a some Drop&Shine and mount your slide to detect amyloids within minutes.
Amytracker 630 is our orange optotracer for labeling protein aggregates with repetitive arrangement of β-sheets. It labels Aβ plaques and neurofibrillary tangles in tissue sections with AD pathology and α-synuclein aggregates in tissue sections with PD pathology. Contact us to learn more about Amytracker applications.
As all our optotracers, Amytracker 630 is exceptionally photostable and fluorogenic. When bound to a target, Amytracker 630 can be imaged using epifluorescence, confocal and superresolution microscopy. Spectral information can be acquired using a fluorescence spectrophotometer. Use recommended filter sets as well as excitation- and emission wavelengths according to the following table.
Table: Excitation- and emission wavelengths as well as recommended filter sets.
Exmax
Emmax
Recommended filter-sets
Amytracker 630
520 nm
630 nm
PI, Cy3, TxRed, mCherry, Cy3.5
Amytracker 630 is available as 1 mg/ml solution in ultrapure water (Aqueous) with volumes ranging from 10 - 200 µL (See volumes and prices in the drop-down list below). The product should be diluted 1:1000 before use. For use in live-cells, sometimes 1:500 is necessary due to uptake limitations. To prevent evaporation of the aqueous solvent, close the container carefully after use, spin down liquid and use up small volumes quickly.
Amytracker 540 is our yellow optotracer for labeling protein aggregates with repetitive arrangement of β-sheets. It labels Aβ plaques and neurofibrillary tangles in tissue sections with AD pathology and α-synuclein aggregates in tissue sections with PD pathology. Contact us to learn more about Amytracker applications.
As all our optotracers, Amytracker 540 is exceptionally photostable and fluorogenic. When bound to a target, Amytracker 540 can be imaged using epifluorescence, confocal and superresolution microscopy. Spectral information can be acquired using a fluorescence spectrophotometer. Use recommended filter sets as well as excitation- and emission wavelengths according to the following table.
Table: Excitation- and emission wavelengths as well as recommended filter sets.
Exmax
Emmax
Recommended filter-sets
Amytracker 540
480 nm
540 nm
FITC, GFP, YFP
Amytracker 540 is available as 1 mg/ml solution in ultrapure water (Aqueous) with volumes ranging from 10 - 200 µL (See volumes and prices in the drop-down list below). The product should be diluted 1:1000 before use. For use in live-cells, sometimes 1:500 is necessary due to uptake limitations. To prevent evaporation of the aqueous solvent, close the container carefully after use, spin down liquid and use up small volumes quickly.
Amytracker 520 is our green optotracer for labeling protein aggregates with repetitive arrangement of β-sheets. It labels Aβ plaques and neurofibrillary tangles in tissue sections with AD pathology and α-synuclein aggregates in tissue sections with PD pathology. Contact us to learn more about Amytracker applications.
As all our optotracers, Amytracker 520 is exceptionally photostable and fluorogenic. When bound to a target, Amytracker 520 can be imaged using epifluorescence, confocal and superresolution microscopy. Spectral information can be acquired using a fluorescence spectrophotometer. Use recommended filter sets as well as excitation- and emission wavelengths according to the following table.
Table: Excitation- and emission wavelengths as well as recommended filter sets.
Exmax
Emmax
Recommended filter-sets
Amytracker 520
460 nm
520 nm
FITC, GFP
Amytracker 520 is available as 1 mg/ml solution in ultrapure water (Aqueous) with volumes ranging from 10 - 200 µL (See volumes and prices in the drop-down list below). The product should be diluted 1:1000 before use. For use in live-cells, sometimes 1:500 is necessary due to uptake limitations. To prevent evaporation of the aqueous solvent, close the container carefully after use, spin down liquid and use up small volumes quickly.
Amytracker 480 is our blue optotracer for labeling protein aggregates with repetitive arrangement of β-sheets. It labels Aβ plaques and neurofibrillary tangles in tissue sections with AD pathology and α-synuclein aggregates in tissue sections with PD pathology. Specifically, Amytracker 480 has been used to study amyloid formation during abnormal coagulation. Contact us to learn more about Amytracker applications.
As all our optotracers, Amytracker 480 is exceptionally photostable and fluorogenic. When bound to a target, Amytracker 480 can be imaged using epifluorescence, confocal and superresolution microscopy. Spectral information can be acquired using a fluorescence spectrophotometer. Use recommended filter sets as well as excitation- and emission wavelengths according to the following table.
Table: Excitation- and emission wavelengths as well as recommended filter sets.
Exmax
Emmax
Recommended filter-sets
Amytracker 480
420 nm
480 nm
DAPI
Amytracker 480 is available as 1 mg/ml solution in ultrapure water (Aqueous) with volumes ranging from 10 - 200 µL (See volumes and prices in the drop-down list below). The product should be diluted 1:1000 before use. For use in live-cells, sometimes 1:500 is necessary due to uptake limitations. To prevent evaporation of the aqueous solvent, close the container carefully after use, spin down liquid and use up small volumes quickly.
Amytracker can be used to label protein aggregates in tissue sections or cells prepared by the most common techniques. It can be used in freshly sliced tissue without fixation but also in fixed cells or sections obtained from flash-frozen or paraffin embedded tissues. Generally, fixation in 4% PFA works well... Read more →
Amytracker can be used for intravenous- or intraperitoneal injection in small animals to label protein aggregates in vivo. It will readily cross the blood brain barrier and can be imaged by intra-vital microscopy or after removing the tissue and preparation of microscope slides. For systemic injection, we recommend to use... Read more →
This protocol describes how Amytracker can be utilized for fibrillation assays and detection of amyloids in liquid samples. As all Amytracker variants are highly fluorescent only when they are bound to their target, they are ideally suited for spectrophotometric analysis. We recommend to perform a titration to use Amytracker in... Read more →
All Amytracker variants cross the cell membrane of living cells without permeabilization. Due to their low background fluorescence and minimal interference with biological autofluorescence, we recommend Amytracker 630 or Amytracker 680 for live-cell imaging. As Amytracker do not bleach easily, they are excellently suited for repeated illumination during time-lapse imaging.... Read more →
Understanding how amyloid-beta (Aβ) aggregates in Alzheimer’s disease (AD) is crucial for advancing diagnostics and treatment. Adam Kreutzer and their colleagues at the University of California Irvine developed a structurally defined Aβ trimer mimic, designed to resemble natural Aβ oligomers found in the brain. Using this trimer as an immunogen,... Read more →
Video: Astrocyte-to-astrocyte transfer of AD tau fibrils through tunneling nanotubes (TNTs). Time-lapse microscopy of Amytracker-labelled AD tau fibrils (shown in red) demonstrating direct cell-to-cell transmission between human astrocytes. Video from Online Resource 10 of Eltom, K., Mothes, T., Libard, S. et al. (2024) acta neuropathol commun (CC-BY-4.0) Tauopathies are a... Read more →
Prion diseases are fatal neurodegenerative disorders caused by the misfolding and aggregation of prion proteins (PrP). Although copper (Cu2+) imbalance has long been suspected to play a role in these conditions, a recent study by Juliani and colleagues at the Federal University of Rio de Janeiro sheds new light on... Read more →
Protein aggregation is traditionally seen as a pathological process, hallmark of neurodegenerative diseases and systemic amyloidoses. However, emerging evidence reveals that amyloid aggregation is not merely the consequence of protein misfolding; rather, cells harness reversible amyloid aggregation to adapt to environmental stress. Understanding how functional amyloids form and disassemble could... Read more →
Small molecules with the ability to inhibit the nucleation process and stop the aggregation of α-synuclein have immense potential to help people suffering from Parkinson's. Availability of several aSyn protein structures has now opened the possibility to develop structure-based drugs that can specifically bind to and prevent α-synuclein aggregation. In... Read more →
Phenylketonuria is an inherited disorder characterised by the inability to break down the amino acid L-phenylalanine (L-Phe). The disease is primarily caused by mutations in the gene that encodes phenylalanine hydroxylase and there are >1000 human described variants, but the R261Q mutation is one of the most common mutations. A... Read more →
Neurodegenerative diseases often involve the accumulation of misfolded proteins, that cells fail to refold or degrade and that eventually form aggregates. Among these, oligomers, small still-soluble aggregates, are the most toxic and can lead to neuronal death. Identifying the aggregation-prone regions of these proteins is key for developing new therapeutic approaches. In over... Read more →
The 14-3-3 proteins regulate various cellular functions, including enzymatic activity and protein stability. The 14-3-3ζ isoform has been linked to neurodegenerative diseases due to its interaction with proteins like tau and α-synuclein, which form amyloid fibrils in Alzheimer’s and Parkinson’s. However, its direct role in amyloid plaque formation remains unclear.... Read more →
Hydrogels can be used as a 3D scaffold for cells to grow in tissue models and biofabrication applications. Such hydrogels can be made from proteins that form amyloid fibrils. Different biological applications have distinct requirements for the properties of these hydrogels. Designing a unique biopolymer for each application is cumbersome... Read more →
Researchers from the University of Florence investigated the nature of TAR DNA-binding protein 43 (TDP-43) cytoplasmic inclusions, which are key pathological markers in neurodegenerative diseases like amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD). The study focused on whether these inclusions exhibit amyloid-like characteristics, as there has been debate... Read more →
Distal myopathies are genetically heterogeneous diseases that primarily affect skeletal muscles, particularly in the hands and feet, although they can progress to other muscles. Previous research has identified more than 25 genes associated with these conditions, but many patients still remain undiagnosed. SMPX (small muscle protein X-linked), a gene involved... Read more →
Alzheimer's disease (AD) affects women more than men. However, we don’t really know why. Women tend to live longer, which may contribute to a higher incidence of AD, but other factors, such as hormonal changes during menopause, could also influence disease progression. In a study, published in Translational Psychiatry, researchers... Read more →
Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia are associated with the aggregation of certain RNA-binding proteins that are part of stress granules, including TAR DNA-binding protein 43 (TDP-43), Fused in Sarcoma (FUS) and Heterogeneous nuclear ribonucleoprotein A (hnRNPA). Stress granules are cytoplasmic membraneless organelles that are formed in response to... Read more →
Faulty α-synuclein (α-Syn) aggregates in cells forming toxic α-Syn oligomers and finally Lewy Bodies which are the pathological hallmark of synucleinopathies. While Lewy Bodies are relatively easy to discern in a microscope, it turns out to be very difficult to investigate the early-intermediate forms of aggregates. A study published in... Read more →
Parkinson's disease (PD) and Multiple System Atrophy (MSA) are both characterized by accumulation and misfolding of ɑ-synuclein (ɑ-syn). However, there are distinct differences between their pathology likely relating back to different strains of ɑ-syn aggregates. The goal of a study by De Luca et al. from IRCCS and SISSA in... Read more →
What causes the accumulation of toxic amyloid aggregates? An article by the group of Bingwei Lu from the Department of Pathology at Stanford University School of Medicine published in the journal Acta Neuropathologica Communications might have found the answer to this question. Their work shows that a defective ribosome quality... Read more →
Accumulation of abnormal tau protein in the brain has been described as pathological hallmark of a group of neurodegenerative disorders called tauopathies. The most common tauopathy is Alzheimer’s disease (AD). In AD, intracellular inclusions containing aggregates of hyperphosphorylated tau coexist with extracellular amyloid plaques containing aggregated amyloid-β (Aβ). Clinically, tau... Read more →
Multiple myeloma is a complex B-cell malignancy characterised by the accumulation of malignant plasma cells. Progression of multiple myeloma is related to dysregulated inflammatiory processes; especially leucocytes and tumor-associated macrophages (TAMs) are central during the initiation and progression of the disease and high concentration of TAMs often relates to drug... Read more →
Repetitive genomic regions are known to expand across generations, due to errors during their replication, and cause a series of - mainly - neurological diseases collectively called repeat expansion diseases. One of these repetitive genomic regions is the GGGGCC (G4C2) locus in the C9orf72 gene. Its expansion is linked with... Read more →
Alpha-synuclein (α-Syn) is a presynaptic neuronal protein encoded by the SNCA gene. It is expressed heavily in the brain and regulates synaptic vesicle trafficking and subsequent neurotransmitter release. Under certain conditions, α-Syn aggregates and forms, together with other components, intracellular inclusions called Lewy bodies (LBs) or Lewy Neurites (LN), which... Read more →
Tau is an intrinsically disordered protein with the key function to stabilise axonal microtubules. In several neurological disorders collectively known as Tauopathies, tau proteins form aggregates that accumulate in cells and cause neuronal damage. The molecular mechanism which leads to tau aggregation is complex and liquid–liquid phase separation (LLPS), a process that... Read more →
In the context of neurodegenerative diseases, large, fibrillar amyloid deposits - such as Lewy bodies, Amyloid plaques, and Neurofibrillary tangles - characterize the pathology of the disease but it has recently become evident that small, spherical aggregates below 20 nm in diameter are mainly responsible of the toxic response that... Read more →
Lipopolysaccharide (LPS) is a cell envelope glycolipid produced by most gram-negative bacteria. When LPS is recognized by Toll-like receptor 4 (TLR4) an innate host-response to bacterial infection is triggered. To achieve a robust antibacterial response while maintaining control of inflammatory processes, LPS has to be cleared from the infection site.... Read more →
Alpha-synuclein (α-Syn) aggregation hallmarks a group of neurodegenerative diseases known as synucleinopathies with Parkinson’s disease as its most well-known representative. The molecular mechanism behind the aggregation of α-Syn is still not completely understood. Many aggregation-prone proteins, like α-Syn, are known to form phase-separated condensates and recent findings suggest that the... Read more →
Infrared (IR) spectroscopy is an invaluable tool to study the biophysical properties of amyloid aggregates. Although historically used as a tool for composition analysis of chemical compounds as it measures the vibrational energy of chemical bonds, IR spectroscopy provides measures to analyse the size and rigidity of amyloid fibrils. Coupling... Read more →
Microglia cells play a vital role in regulating brain development, maintenance of neuronal networks, and injury repair. Their involvement in the progression of protein aggregation leading to neurodegenerative diseases is complex. While they can clear amyloid plaques and prevent their accumulation, dysfunctional microglia regulation may be a key factor in... Read more →
Infection with SARS-CoV-2 leads to patients developing the COVID-19 disease, which is a complex hyperinflammatory syndrome, characterised by acute respiratory distress (ARD). Aside from these severe respiratory symptoms, we now know that the virus can present in unexpected, varied, and long-lasting manners. Recent studies hint towards the amyloidogenicity of the... Read more →
Parkinson’s disease is a brain disorder that causes unintended or uncontrollable movements, such as shaking, stiffness, and difficulty with balance and coordination. Symptoms usually begin gradually and worsen over time. As the disease progresses, people may have difficulty walking and talking. The basis of these symptoms is progressive neurodegeneration and... Read more →
The nuclear proteome is rich in proteins which are prone to aggregate upon conformational stress. This might explain why intranuclear inclusions can often be found in neurodegenerative disorders associated with protein aggregation. Using a combination of fluorescence imaging, biochemical analyses, and proteomics, researchers at Max Planck Institute for Biochemistry around... Read more →
A team of researchers from Massachusetts General Hospital and Harvard Medical School as well as Linköping University have used a fluorescent probe of the same type as Amytracker for multiphoton imaging of Amyloid-β deposits in transgenic mice in vivo. The fluorescent molecule clearly targeted and labeled core plaques in the... Read more →
In a study, recently published in Nature, a fluorescent tracer molecule similar to Amytracker has been used to detect α-synuclein aggregates in cerebrospinal fluid from patients with synucleopathy. Interestingly, the fluorescent tracer molecule was binding aggregates from patients with Multiple Systems Atrophy with higher affinity than aggregates from patients with... Read more →
Lipopolysaccharides (LPS) from the Gram-negative cell envelope can be shed from dormant bacteria or from continual bacteria entry into the blood and serve to contribute to the chronic inflammation. The presence of highly substoichiometric amounts of LPS from Gram-negative bacteria caused fibrinogen clotting to lead to the formation of an... Read more →
Type-2 diabetes is a progressive condition marked by resistance towards the blood-sugar regulating hormone insulin. Recently, Type-2 diabetes is become recognized as an inflammatory condition which is often accompanied by cardiovascular complications. The teams around Prof. Etheresia Pretorius from Stellenbosh University and Prof. Douglas B. Kell from the University of... Read more →
In a new study in the Journal of visualized experiments, the team around Prof. Peter Nilsson and Prof. Per Hammarström from Linköpings University describe how luminescent conjugated oligothiophenes (LCOs) can be used with Hyperspectral Imaging (HIS) and Fluorescence Lifetime Imaging (FLIM) to detect amyloid species. In a practical approach, the... Read more →
An approved method for visualization of Amyloid β (Aβ) plaques in patients suffering from Alzheimer's disease is Positron Emission Tomography (PET). This method requires a radiolabeled amyloid ligand. A frequently used molecule is Pittsburgh Compound B (PIB) which is a derivative of Thioflavin T. Radiolabeled PIB is well-suited to visualize... Read more →
A team of scientists around Frederic Rousseau from Switch Laboratory at KU Leuven have designed a biologically active amyloid from a peptide sequence occurring in vascular endothelial growth factor 2 (VEGFR2). The peptide, which the researchers named vascin forms artificial amyloids. The results show, however, that vascin amyloids are not... Read more →
By 2050, the number of people aged >65 is expected to double. This will lead to a significant rise in the prevalence of age-related diseases. Many of these conditions are linked to two major processes: protein aggregation and chronic inflammation. The precise relationship between these two components and how they... Read more →
Amytracker are optotracers with structure-dependent photo-physical properties. All Amytracker variants are designed to bind to the Congo red binding pocket on the amyloid fibril and require a theoretical minimum of eight in-register parallel-β-strands for binding. Therefore, Amytracker reliably labels amyloids derived from a variety of amyloidogenic proteins or peptides from... Read more →
Amytracker are optotracers with structure-dependent photo-physical properties. All Amytracker variants are designed to bind to the Congo red binding pocket on the amyloid fibril and require a theoretical minimum of eight in-register parallel-β-strands for binding. Therefore, Amytracker reliably labels amyloids derived from a variety of amyloidogenic proteins or peptides from... Read more →
Around 30% of the people infected with the SARS-CoV-2 virus report persistent symptoms for a long time after the acute infection ends. While the development of this long-term manifestation after COVID, referred to as Long COVID, has been framed as mysterious, it is actually a well described outcome of many... Read more →
The macromolecules and organelles within cells are not permanent and need to get replaced over time. To do this, cells need to both produce new components and to degrade the old ones. The degradation of the bigger cellular structures depends on a process called autophagy. During autophagy, the cell envelopes... Read more →
Tau is an intracellular protein which associates with microtubules and stabilizes them. Physiologically, Tau is phosphorylated to facilitate release from the microtubules and thereby favor microtubule shortening. In a pathological state, Tau is hyperphosphorylated which increases its tendency to aggregate in the cytoplasm. This means that conditions which promote abnormal... Read more →
Aggregates of α-synuclein are the major component of Lewy bodies which are the pathological hallmark of a series of neurodegenerative disorders, called Lewy body diseases or Synucleinopathies. In physiological conditions, α-synuclein regulates synaptic vesicle-release and possibly cytoskeletal assembly. However, this small pre-synaptic protein is characterized by an intrinsically disordered structure... Read more →
Human cells typically assemble a myriad of different proteins which constitute the work-force of the cellular environment and each of them is dedicated to a very specific function. The ability of a protein to perform its task is closely related to its structure: pockets, arms, and fingers are needed to... Read more →
Amyloidosis is the name for a group of conditions caused by a build-up of amyloid protein deposits in organs and tissues throughout the body. A great many diseases can be classified as amyloidosis. The most well known are the cerebral amyloidoses Alzheimer's and Parkinson's disease. Lesser known are the systemic... Read more →
Phase separation of biomolecules has recently been recognised as an important cellular process governing homogeneous organisation which is a driving force for cellular self-assembly. Multivalent interactions between biomolecules give rise to condensed phases with a spectrum of material properties from liquids to solids. The liquid-like properties (wetting, fusion, and dynamic... Read more →
We named our Amytracker molecules after their peak emission wavelength when they are bound to their target. That means, when Amytracker is bound to a target, it will emit fluorescence at peak emission indicated by the number associated with its name. To view the excitation and emission spectra, please select... Read more →
Amytracker fluorescence is one order of magnitude brighter than Congo Red. The affinity of Amytracker is in the nM range and thus, Amytracker is typically used at several fold lower concentrations. In a comparative study using human amyloidosis tissue, Amytracker detected amyloid deposits in 15 % of Congo Red negative... Read more →
We tested a wide range of human tissues and didn't observe unspecific staining in most cell types. Positive Amytracker staining was obtained in Paneth cell granules in the intestine stained and the binding target in these cells is yet unclear. Due to the high sensitivity of Amytracker towards amyloids, and... Read more →
It is likely that Amytracker works on all kinds of tissues and species. Amytracker targets and detects the physical topography of the tertiary- and quaternary structure of mature and pre-fibrillar amyloid deposits. As such it is applicable to a wide range of animal models and different Amytracker molecules have been... Read more →
Amytracker have been shown to bind with high affinity to aggregates composed of transthyretin (TTR) in Drosophila models of transthyretin amyloidosis (ATTR), as well as in human tissues The optotracers have been used to detect aggregates in following forms of human amyloid diseases: AA amyloidosis associated with accumulation of serum... Read more →
All Amytracker molecules are designed to interact with the same binding site on the amyloid oligomer. Competition assays have shown that Amytracker competes for the congo red binding site but show much higher affinity. In essence the binding cavity and binding mode of Amytracker is is dictated by a groove... Read more →
Generally, we recommend light fixation using ice-cold ethanol or acetone. This is because formalin-fixation has been shown to reduce the ability to stain inclusion bodies. Otherwise there shouldn't be any issues. You can use paraffin sections or cryosections. Note that epitope exposure and antigen retrieval is not needed when applying... Read more →
When Amytracker are not bound to a target, they exhibit an extremely low background fluorescence. Amytracker have also been shown to neither accelerate nor inhibit amyloid formation when used in recommended (substochoimetric) concentrations. Therefore, Amytracker are suitable for fibrillation assays and spectrophotometric detection. Amytracker have been shown to identify pre-fibrillar... Read more →
We supply Amytracker molecules with high affinity toward amyloid proteins. For staining of cryo- or paraffin sections, diluting the supplied solutions 1:1000 should be sufficient. If you want to increase the intensity, you might increase the concentration and use 1:500 dilution instead. For live cell staining, we usually recommend to... Read more →
As functional aspects of amyloids as well as the dynamic processes involving amyloid formation and amyloid toxicity are of growing interest many researchers are interested to study these processes in living cells. Non-invasive techniques like fluorescence microsopy have been perfected in recent years for the study of living cells. Unfortunately,... Read more →
Under some conditions, peptides or proteins may convert from their soluble forms into unsoluble highly ordered fibrillar aggregates. These aggregates may cause disease through various mechanisms. Prominent examples of aggregating peptides related to neurodegenerative diseases are Amyloid β peptides which play an important role in Alzheimer's disease and aggregating α-synuclein... Read more →
Amyloid detection has been notoriously difficult since current methods are either laborious, toxic and/or tend to detect mature fibrils but not protofibrils or premature aggregates. Amytracker are fluorescent tracer molecules binding to amyloids with high sensitivity. Amytracker have been shown to bind to prefibrillar states of amyloids and might therefore... Read more →
The kinetics of amyloid formation from conformational conversion of a peptide or protein into its fibrillar form (amyloid) is studied using fibrillation assays using a spectrophotometer. This technique requires extremely low background fluorescence of the unbound probe and Thioflavin T has been widely used for this reason. The kinetic profile... Read more →
Super-resolution microscopy is becoming an important tool to study biological structures. As super-resolution techniques like STED overcome the physical diffraction limit of light, new microscopes with ever-decreasing resolution limits are being developed. Using these exciting techniques, the constraints are now imposed by the probes used for labelling. With STED microscopy,... Read more →
Intravital imaging is allowing researchers to capture images of biological processes in live animals. It has become an advanced tool to study the progression of Alzheimer's and other neurodegenerative diseases in transgenic mice. In vivo imaging using two-photon microscopy is an advantageous technique for observing tissues and organs at high... Read more →
Linh Tran about Amytracker 480 and Amytracker 680 "I have the opportunity to work with Amytracker dyes for my PhD project and find them to be exceptional. These dyes deliver superb brightness and an excellent signal-to-noise ratio, making them an outstanding tool for the fluorescent visualization of amyloid-beta. On tissue... Read more →
Manuela Leri about Amytracker 630 "I used the Amytracker 630 probe to visualize intracellular aggregates on cell cultures. I obtained excellent results using confocal microscopy. The cells were permeabilized and the probe recognized the primary antibody used very well and emitted a good signal. The signal is stable." Manuela Leri... Read more →
Azad Farzadfard about Amytracker 580 and Amytracker 680 "Amytracker was a great substitute for ThT in visualizing the alpha-synuclein fibrils inside the water-in-oil emulsion droplets made in microfluidic devices. ThT leakage from these droplets was an issue that was resolved by Amytracker products. I started by using Amytracker 480 that... Read more →
Tom Cornelissen, PhD, reMYND Science Director Contract Research: “At reMYND's Contract Research Organization (CRO), we specialize in conducting efficacy and proof of concept studies using mouse models for Alzheimer's and Parkinson's disease. In our search for innovation, we have integrated Amytracker 520 from Ebba Biotech into our research protocols, and... Read more →
Prof. Fabrizio Chiti about Amytracker 630: "I like Amytracker probes because they can be used to detect amyloid-like species inside cells. We have used Amytracker 630 to exclude amyloid-like species of TDP-43 expressed in NSC34 cultured cells. We have also used cells treated with BSA and preformed Abeta fibrils as... Read more →
Adam Kreutzer about Amytracker 680: “I have been very happy with the Amytracker dyes I have used thus far. I have easily worked the Amytracker dyes into my free-floating, fixed brain tissue immunostaining workflow. The nice thing about the Amytracker dyes is that I don’t have to dehydrate the tissue... Read more →
Keiza Jack about Amytracker 540: “I have used Amytracker 540 in my PhD project as a tool to measure the structural differences of prion structures and prion-seeded amyloid fibrils. Amytracker 540 reports sensitively on subtle structural differences between protein structures, giving me a fast and reproduceable method to compare protein... Read more →
Dr. Jaakko Sarparanta about Amytracker 680: ”We used Amytracker 680 to study the amyloid-like nature of pathological protein aggregates in muscle sections. The bright positive staining was easily interpreted and provided the much needed support for our Congo Red results.” Dr. Jaakko Sarparanta, Folkhälsan Research Center, Helsinki, Finland. Testimonial given... Read more →
M. Garcia about Amytracker 520: "We are studying Alzheimer’s disease in mouse models and use a variety of anti-amyloid-beta antibodies and traditional dyes to look at amyloid-beta aggregation. Amytracker 520 gave a very clean staining with high signal to noise. It was easy to use as a part of routine... Read more →
Ebba Biotech welcomes you to tune in to our webinar featuring Dr. Timothy Audas from Simon Fraser University. Dr. Audas will present his research using Amytracker to explore the detection of functional amyloids in stress-treated mammalian cells. Dr. Audas is an Associate Professor and Canada Research Chair at Simon Fraser... Read more →
Ebba Biotech welcomes you to tune in to our webinar featuring Assistant Professor Oxana Klementieva from Lund's University. During her talk titled "Amytracker - A New Frontier in Imaging of Amyloid Structures in Tissues", Oxana Klementieva will detail her cutting-edge research into mechanisms of amyloid aggregation using novel imaging techniques.... Read more →
Ebba Biotech's first webinar in 2023 is dedicated to "Amyloid Fibril Polymorphism" which has recently been shown to be a hallmark of many proteinopathies. One of the leading authorities in this field is Professor Per Hammarström from Linköping University. During this talk titled "Amyloid fibril polymorphism in proteinopathies", Prof. Hammarström... Read more →
Ebba Biotech welcomes you to listen to Prof. Resia Pretorius present her research findings using the Amytracker molecules. Her presentation titled “Consequences of coagulation in health and disease: The use of fluorescent markers” will detail past work with the Amytracker molecules within her group and her new exciting work with... Read more →
On the first of June 2021, Ferdinand Choong, Ebba Biotech's co-founder, and Assistant Professor at Karolinska Institutet and AIMES (Center for the Advancement of Integrated Medical and Engineering), presented his research using Ebba Biotech's optotracers at the digital event Lab & Diagnostics of the Future 2021, held by Life Science... Read more →
A paper in the scientific video journal Jove (Nyström et al. (2017) Jove 128, 1–7) describes the application of Amytracker-like Molecules in combination with fluorescence microscopy techniques for detection and exploration of protein aggregates.
Read more →
Peter Nilson has been elected as future research leader from the Swedish Foundation for Strategic Research (SSF). His work about the development of multifunctional tools for diagnosis and therapy has led to the development of our Amytracker molecules.
Read more →
We named our Amytracker molecules after their peak emission wavelength when they are bound to their target. That means, when Amytracker is bound to a target, it will emit fluorescence at peak emission indicated by the number associated with its name.
To view the excitation and emission spectra, please select your Amytracker below :
Excitation (blue lines) and emission (red lines) spectra of unbound Amytracker (dotted lines) and Amytracker bound to a target (solid lines).
2025
Puthia, M., Marzinek, J. K., Vesela, K., Larsson, A., Schmidtchen, A., Bond, P. J., & Petrlova, J. (2025). Apolipoprotein E3 and E4 isoforms exhibit differing effects in countering endotoxins. Journal of Biological Chemistry, 301(3), 108236. https://doi.org/10.1016/j.jbc.2025.108236
2024
Pinzi, L., Conze, C., Bisi, N., Torre, G. D., Soliman, A., Monteiro-Abreu, N., Trushina, N. I., Krusenbaum, A., Dolouei, M. K., Hellwig, A., Christodoulou, M. S., Passarella, D., Bakota, L., Rastelli, G., & Brandt, R. (2024). Quantitative live cell imaging of a tauopathy model enables the identification of a polypharmacological drug candidate that restores physiological microtubule interaction. Nature Communications, 15(1), 1679. https://doi.org/10.1038/s41467-024-45851-6
Šulskis, D., Žiaunys, M., Sakalauskas, A., Sniečkute, R., & Smirnovas, V. (2024). Formation of amyloid fibrils by the regulatory 14-3-3ζ protein. Open Biology, 14(1). https://doi.org/10.1098/rsob.230285
Dranseike, D., Ota, Y., Edwardson, T. G. W., Guzzi, E. A., Hori, M., Nakic, Z. R., Deshmukh, D. v., Levasseur, M. D., Mattli, K., Tringides, C. M., Zhou, J., Hilvert, D., Peters, C., & Tibbitt, M. W. (2024). Designed modular protein hydrogels for biofabrication. Acta Biomaterialia, 177, 107–117. https://doi.org/10.1016/J.ACTBIO.2024.02.019
Balana, A. T., Mahul-Mellier, A. L., Nguyen, B. A., Horvath, M., Javed, A., Hard, E. R., Jasiqi, Y., Singh, P., Afrin, S., Pedretti, R., Singh, V., Lee, V. M. Y., Luk, K. C., Saelices, L., Lashuel, H. A., & Pratt, M. R. (2024). O-GlcNAc forces an α-synuclein amyloid strain with notably diminished seeding and pathology. Nature Chemical Biology, 20(5), 646–655. https://doi.org/10.1038/s41589-024-01551-2
Kreutzer, A. G., Parrocha, C. M. T., Haerianardakani, S., Guaglianone, G., Nguyen, J. T., Diab, M. N., Yong, W., Perez-Rosendahl, M., Head, E., & Nowick, J. S. (2024). Antibodies Raised Against an Aβ Oligomer Mimic Recognize Pathological Features in Alzheimer’s Disease and Associated Amyloid-Disease Brain Tissue. ACS Central Science, 10(1), 104–121. https://doi.org/10.1021/acscentsci.3c00592
Raymundo, J. R., Zhang, H., Smaldone, G., Zhu, W., Daly, K. E., Glennon, B. J., Pecoraro, G., Salvatore, M., Devine, W. A., Lo, C. W., Vitagliano, L., & Marneros, A. G. (2024). KCTD1/KCTD15 complexes control ectodermal and neural crest cell functions, and their impairment causes aplasia cutis. The Journal of Clinical Investigation, 134(4). https://doi.org/10.1172/JCI174138
Morelli, C., Faltova, L., Capasso Palmiero, U., Makasewicz, K., Papp, M., Jacquat, R. P. B., Pinotsi, D., & Arosio, P. (2024). RNA modulates hnRNPA1A amyloid formation mediated by biomolecular condensates. Nature Chemistry, 16(7), 1052–1061. https://doi.org/10.1038/s41557-024-01467-3
Kitamura, A., Fujimoto, A., Kawashima, R., Lyu, Y., Sasaki, K., Hamada, Y., Moriya, K., Kurata, A., Takahashi, K., Brielmann, R., Bott, L. C., Morimoto, R. I., & Kinjo, M. (2024). Hetero-oligomerization of TDP-43 carboxy-terminal fragments with cellular proteins contributes to proteotoxicity. Communications Biology, 7(1). https://doi.org/10.1038/s42003-024-06410-3
de Oliveira, D. H., Gowda, V., Sparrman, T., Gustafsson, L., Sanches Pires, R., Riekel, C., Barth, A., Lendel, C., & Hedhammar, M. (2024). Structural conversion of the spidroin C-terminal domain during assembly of spider silk fibers. Nature Communications, 15(1). https://doi.org/10.1038/s41467-024-49111-5
Sun, H., Yang, B., Li, Q., Zhu, X., Song, E., Liu, C., Song, Y., & Jiang, G. (2024). Polystyrene nanoparticles trigger aberrant condensation of TDP-43 and amyotrophic lateral sclerosis-like symptoms. Nature Nanotechnology. https://doi.org/10.1038/s41565-024-01683-5
Li, B., Suresh, P., Brelstaff, J., Kedia, S., Bryant, C. E., & Klenerman, D. (2024). The delayed kinetics of Myddosome formation explains why amyloid-beta aggregates trigger Toll-like receptor 4 less efficiently than lipopolysaccharide. eLife, 13, RP92350. https://doi.org/10.7554/eLife.92350
Bacioglu, M., Schweighauser, M., Gray, D., Lövestam, S., Katsinelos, T., Quaegebeur, A., van Swieten, J., Jaunmuktane, Z., Davies, S. W., Scheres, S. H. W., Goedert, M., Ghetti, B., & Spillantini, M. G. (2024). Cleaved TMEM106B forms amyloid aggregates in central and peripheral nervous systems. Acta Neuropathologica Communications, 12(1). https://doi.org/10.1186/s40478-024-01813-z
Eltom, K., Mothes, T., Libard, S., Ingelsson, M., & Erlandsson, A. (2024). Astrocytic accumulation of tau fibrils isolated from Alzheimer’s disease brains induces inflammation, cell-to-cell propagation and neuronal impairment. Acta Neuropathologica Communications, 12(1). https://doi.org/10.1186/s40478-024-01745-8
2023
Arad, E., Pedersen, K. B., Malka, O., Mambram Kunnath, S., Golan, N., Aibinder, P., Schiøtt, B., Rapaport, H., Landau, M., & Jelinek, R. (2023). Staphylococcus aureus functional amyloids catalyze degradation of β-lactam antibiotics. Nature Communications, 14(1). https://doi.org/10.1038/s41467-023-43624-1
Juliani do Amaral, M., Mohapatra, S., Ribeiro Passos, A., Sousa Lopes da Silva, T., Sampaio Carvalho, R., da Silva Almeida, M., Sá Pinheiro, A., Wegmann, S., & Cordeiro, Y. (2023). Copper drives prion protein phase separation and modulates aggregation. Science Advances, 9, eadi7347. https://doi.org/10.1126/sciadv.adi7347
Chandhok, S., Pereira, L., Momchilova, E. A., Marijan, D., Zapf, R., Lacroix, E., Kaur, A., Keymanesh, S., Krieger, C., & Audas, T. E. (2023). Stress-mediated aggregation of disease-associated proteins in amyloid bodies. Scientific Reports, 13(1). https://doi.org/10.1038/s41598-023-41712-2
Chia, S., Faidon Brotzakis, Z., Horne, R. I., Possenti, A., Mannini, B., Cataldi, R., Nowinska, M., Staats, R., Linse, S., Knowles, T. P. J., Habchi, J., & Vendruscolo, M. (2023). Structure-Based Discovery of Small-Molecule Inhibitors of the Autocatalytic Proliferation of α-Synuclein Aggregates. Mol. Pharmaceutics, 20, 183–193. https://doi.org/10.1021/acs.molpharmaceut.2c00548
Frenkel, A., Zecharia, E., Gómez-Pérez, D., Sendersky, E., Yegorov, Y., Jacob, A., Benichou, J. I. C., Stierhof, Y. D., Parnasa, R., Golden, S. S., Kemen, E., & Schwarz, R. (2023). Cell specialization in cyanobacterial biofilm development revealed by expression of a cell-surface and extracellular matrix protein. Npj Biofilms and Microbiomes 2023 9:1, 9(1), 1–10. https://doi.org/10.1038/s41522-023-00376-6
Gvazava, N., Konings, S. C., Cepeda-Prado, E., Skoryk, V., Umeano, C. H., Dong, J., Silva, I. A. N., Ottosson, D. R., Leigh, N. D., Wagner, D. E., & Klementieva, O. (2023). Label-Free High-Resolution Photothermal Optical Infrared Spectroscopy for Spatiotemporal Chemical Analysis in Fresh, Hydrated Living Tissues and Embryos. Journal of the American Chemical Society. https://doi.org/10.1021/jacs.3c08854
Petrlova, J., Hartman, E., Petruk, G., Lim, J. C. H., Adav, S. S., Kjellström, S., Puthia, M., & Schmidtchen, A. (2023). Selective protein aggregation confines and inhibits endotoxins in wounds: Linking host defense to amyloid formation. iScience, 26(10). https://doi.org/10.1016/j.isci.2023.107951
Kommaddi, R. P., Verma, A., Muniz-Terrera, G., Tiwari, V., Chithanathan, K., Diwakar, L., Gowaikar, R., Karunakaran, S., Malo, P. K., Graff-Radford, N. R., Day, G. S., Laske, C., Vöglein, J., Nübling, G., Ikeuchi, T., Kasuga, K., & Ravindranath, V. (2023). Sex difference in evolution of cognitive decline: studies on mouse model and the Dominantly Inherited Alzheimer Network cohort. Translational Psychiatry, 13(1), 1–12. https://doi.org/10.1038/s41398-023-02411-8
Ornithopoulou, E., Åstrand, C., Gustafsson, L., Crouzier, T., & Hedhammar, M. (2023). Self-Assembly of RGD-Functionalized Recombinant Spider Silk Protein into Microspheres in Physiological Buffer and in the Presence of Hyaluronic Acid. ACS Applied Bio Materials, 6(9), 3696–3705. https://doi.org/10.1021/acsabm.3c00373
Piroska, L., Fenyi, A., Thomas, S., Plamont, M.-A., Redeker, V., Melki, R., & Gueroui, Z. (2023). α-Synuclein liquid condensates fuel fibrillar α-synuclein growth. Science Advances, 9(33), eadg5663. https://doi.org/10.1126/sciadv.adg5663
Prater, C., Bai, Y., Konings, S. C., Martinsson, I., Swaminathan, V. S., Nordenfelt, P., Gouras, G., Borondics, F., & Klementieva, O. (2023). Fluorescently Guided Optical Photothermal Infrared Microspectroscopy for Protein-Specific Bioimaging at Subcellular Level. Journal of Medicinal Chemistry, 66(4), 2542–2549. https://doi.org/10.1021/acs.jmedchem.2c01359
2022
Cascella, R., Banchelli, M., Abolghasem Ghadami, S., Ami, D., Gagliani, M. C., Bigi, A., Staderini, T., Tampellini, D., Cortese, K., Cecchi, C., Natalello, A., Adibi, H., Matteini, P., & Chiti, F. (2022). An in situ and in vitro investigation of cytoplasmic TDP-43 inclusions reveals the absence of a clear amyloid signature. Annals of Medicine, 55(1), 72–88. https://doi.org/10.1080/07853890.2022.2148734
Choi, M. L., Chappard, A., Singh, B. P., Maclachlan, C., Abramov, A. Y., Horrocks, M. H., & Gandhi, S. (2022). Pathological structural conversion of α-synuclein at the mitochondria induces neuronal toxicity. Nature Neuroscience. https://doi.org/10.1038/s41593-022-01140-3
de Luca, C. M. G., Consonni, A., Cazzaniga, F. A., Bistaffa, E., Bufano, G., Quitarrini, G., Celauro, L., Legname, G., Eleopra, R., Baggi, F., Giaccone, G., & Moda, F. (2022). The alpha-synuclein RT-QuIC products generated by the olfactory mucosa of patients with parkinson’s disease and multiple system atrophy induce inflammatory responses in SH-SY5Y cells. Cells, 11(1). https://doi.org/10.3390/cells11010087
Wood, J. I., Wong, E., Cummings, D. M., Hardy, J., Correspondence, F. A. E., Joghee, R., Balbaa, A., Vitanova, K. S., Stringer, K. M., Vanshoiack, A., Phelan, S.-L. J., Launchbury, F., Desai, S., Tripathi, T., Rg Hanrieder, J., & Edwards, F. A. (2022). Plaque contact and unimpaired Trem2 is required for the microglial response to amyloid pathology. Cell Reports. https://doi.org/10.1016/j.celrep.2022.111686
Petrlova, J., Samsudin, F., Bond, P. J., & Schmidtchen, A. (2022). SARS-CoV-2 spike protein aggregation is triggered by bacterial lipopolysaccharide. FEBS Letters. https://doi.org/10.1002/1873-3468.14490
Morten, M. J., Sirvio, L., Rupawala, H., Hayes, E. M., Franco, A., Radulescu, C., Ying, L., Barnes, S. J., Muga, A., & Ye, Y. (2022). Quantitative super-resolution imaging of pathological aggregates reveals distinct toxicity profiles in different synucleinopathies. PNAS. https://doi.org/10.1073/pnas
Hochmair, J., Exner, C., Franck, M., Dominguez‐Baquero, A., Diez, L., Brognaro, H., Kraushar, M. L., Mielke, T., Radbruch, H., Kaniyappan, S., Falke, S., Mandelkow, E., Betzel, C., & Wegmann, S. (2022). Molecular crowding and RNA synergize to promote phase separation, microtubule interaction, and seeding of Tau condensates. The EMBO Journal, 41(11). https://doi.org/10.15252/EMBJ.2021108882
Kumar, S. T., Mahul-Mellier, A. L., Hegde, R. N., Rivière, G., Moons, R., de Opakua, A. I., Magalhães, P., Rostami, I., Donzelli, S., Sobott, F., Zweckstetter, M., & Lashuel, H. A. (2022). A NAC domain mutation (E83Q) unlocks the pathogenicity of human alpha-synuclein and recapitulates its pathological diversity. Science Advances, 8(17), 44. https://doi.org/10.1126/SCIADV.ABN0044
Lackie, R. E., de Miranda, A. S., Lim, M. P., Novikov, V., Madrer, N., Karunatilleke, N. C., Rutledge, B. S., Tullo, S., Brickenden, A., Maitland, M. E. R., Greenberg, D., Gallino, D., Luo, W., Attaran, A., Shlaifer, I., del Cid Pellitero, E., Schild-Poulter, C., Durcan, T. M., Fon, E. A., … Prado, M. A. M. (2022). Stress-inducible phosphoprotein 1 (HOP/STI1/STIP1) regulates the accumulation and toxicity of α-synuclein in vivo. Acta Neuropathologica. https://doi.org/10.1007/s00401-022-02491-8
2021
Graziotto, M. E., Adair, L. D., Kaur, A., Vérité, P., Ball, S. R., Sunde, M., Jacquemin, D., & New, E. J. (2021). Versatile naphthalimide tetrazines for fluorogenic bioorthogonal labelling. RSC Chemical Biology, 2(5), 1491–1498. https://doi.org/10.1039/D1CB00128K
Michno, W., Stringer, K. M., Enzlein, T., Passarelli, M. K., Escrig, S., Vitanova, K., Wood, J., Blennow, K., Zetterberg, H., Meibom, A., Hopf, C., Edwards, F. A., & Hanrieder, J. (2021). Following spatial Aβ aggregation dynamics in evolving Alzheimer’s disease pathology by imaging stable isotope labeling kinetics. Science Advances, 7(25), 4855–4871. https://doi.org/10.1126/SCIADV.ABG4855/
Aubi, O., Prestegård, K. S., Jung-KC, K., Shi, T. J. S., Ying, M., Grindheim, A. K., Scherer, T., Ulvik, A., McCann, A., Spriet, E., Thöny, B., & Martinez, A. (2021). The Pah-R261Q mouse reveals oxidative stress associated with amyloid-like hepatic aggregation of mutant phenylalanine hydroxylase. Nature Communications 2021 12:1, 12(1), 1–16. https://doi.org/10.1038/s41467-021-22107-1
Frey, B., AlOkda, A., Jackson, M. P., Riguet, N., Duce, J. A., & Lashuel, H. A. (2021). Monitoring alpha-synuclein oligomerization and aggregation using bimolecular fluorescence complementation assays: What you see is not always what you get. Journal of Neurochemistry, 157(4), 872–888. https://doi.org/10.1111/jnc.15147
Frottin, F., Pérez-Berlanga, M., Hartl, F. U., & Hipp, M. S. (2021). Multiple pathways of toxicity induced by C9orf72 dipeptide repeat aggregates and G4C2 RNA in a cellular model. ELife, 10. https://doi.org/10.7554/eLife.62718
Rimal, S., Li, Y., Vartak, R., Geng, J., Tantray, I., Li, S., Huh, S., Vogel, H., Glabe, C., Grinberg, L. T., Spina, S., Seeley, W. W., Guo, S., & Lu, B. (2021). Inefficient quality control of ribosome stalling during APP synthesis generates CAT-tailed species that precipitate hallmarks of Alzheimer’s disease. Acta Neuropathologica Communications, 9(1), 1–24. https://doi.org/10.1186/s40478-021-01268-6
Hofbauer, D., Mougiakakos, D., Mackensen, A., Ricagno, S., & Bruns, H. (2021). B2-microglobulin triggers NLRP3 inflammasome activation in tumor-associated macrophages to promote multiple myeloma progression. Immunity. https://doi.org/10.1016/j.immuni.2021.07.002
Johari, M., Sarparanta, J., Vihola, A., Jonson, P. H., Savarese, M., Jokela, M., Torella, A., Piluso, G., Said, E., Vella, N., Cauchi, M., Magot, A., Magri, F., Mauri, E., Kornblum, C., Reimann, J., Stojkovic, T., Romero, N. B., Luque, H., Huovinen, S., Lahermo, P., Donner, K., Comi, G. P., Nigro, V., Hackman, P., & Udd, B. (2021). Missense mutations in small muscle protein X-linked (SMPX) cause distal myopathy with protein inclusions. Acta Neuropathologica, 0123456789. https://doi.org/10.1007/s00401-021-02319-x
2020
Mahul-Mellier, A. L., Burtscher, J., Maharjan, N., Weerens, L., Croisier, M., Kuttler, F., Leleu, M., Knott, G. W., & Lashuel, H. A. (2020). The process of Lewy body formation, rather than simply α-synuclein fibrillization, is one of the major drivers of neurodegeneration. Proceedings of the National Academy of Sciences of the United States of America, 117(9), 4971–4982. https://doi.org/10.1073/pnas.1913904117
Ghosh, A., Mizuno, K., Tiwari, S. S., Proitsi, P., Gomez Perez-Nievas, B., Glennon, E., Martinez-Nunez, R. T., & Giese, K. P. (2020). Alzheimer’s disease-related dysregulation of mRNA translation causes key pathological features with ageing. Translational Psychiatry, 10(1), 1–18. https://doi.org/10.1038/s41398-020-00882-7
2019
Page, M. J., Thomson, G. J. A., Nunes, J. M., Engelbrecht, A. M., Nell, T. A., de Villiers, W. J. S., de Beer, M. C., Engelbrecht, L., Kell, D. B., & Pretorius, E. (2019). Serum amyloid A binds to fibrin(ogen), promoting fibrin amyloid formation. Scientific Reports, 9(1), 1–14. https://doi.org/10.1038/s41598-019-39056-x
Adams, B., Nunes, J. M., Page, M. J., Roberts, T., Carr, J., Nell, T. A., Kell, D. B., & Pretorius, E. (2019). Parkinson’s disease: A systemic inflammatory disease accompanied by bacterial inflammagens. Frontiers in Aging Neuroscience, 10(JUL), 1–17. https://doi.org/10.3389/fnagi.2019.00210
Frottin, F., Schueder, F., Tiwary, S., Gupta, R., Körner, R., Schlichthaerle, T., Cox, J., Jungmann, R., Hartl, F. U., & Hipp, M. S. (2019). The nucleolus functions as a phase-separated protein quality control compartment. Science, 365(6451), 342–347. https://doi.org/10.1126/science.aaw9157
2018
de Waal, G. M., Engelbrecht, L., Davis, T., de Villiers, W. J. S., Kell, D. B., & Pretorius, E. (2018). Correlative Light-Electron Microscopy detects lipopolysaccharide and its association with fibrin fibres in Parkinson’s Disease, Alzheimer’s Disease and Type 2 Diabetes Mellitus. Scientific Reports, 8(1), 1–12. https://doi.org/10.1038/s41598-018-35009-y
Pretorius, E., Page, M. J., Hendricks, L., Nkosi, N. B., Benson, S. R., & Kell, D. B. (2018). Both lipopolysaccharide and lipoteichoic acids potently induce anomalous fibrin amyloid formation: Assessment with novel Amytracker TM stains. Journal of the Royal Society Interface, 15(139). https://doi.org/10.1098/rsif.2017.0941
2017
Sehlin, D., Fang, X. T., Meier, S. R., Jansson, M., & Syvänen, S. (2017). Pharmacokinetics, biodistribution and brain retention of a bispecific antibody-based PET radioligand for imaging of amyloid-β. Scientific Reports, 7(1), 1–9. https://doi.org/10.1038/s41598-017-17358-2
Pretorius, E., Page, M. J., Engelbrecht, L., Ellis, G. C., & Kell, D. B. (2017). Substantial fibrin amyloidogenesis in type 2 diabetes assessed using amyloid-selective fluorescent stains. Cardiovascular Diabetology, 16(1), 1–14. https://doi.org/10.1186/s12933-017-0624-5
Terms & Conditions
For detailed information on Terms & Conditions, please click the link below.
